Item number guide |
Deep venous stents
Abre™ venous self-expanding stent system
The Abre™ venous self-expanding stent system is designed for the unique challenges of venous disease.
Features
Simplicity for you.
Durability for them.
Watch the Abre™ stent mechanism of action.
Indications
The Abre™ stent system is intended for use in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.
Clinical evidence
Clinically meaningful impact on quality of life through 36 months — in even the most complex patients.
36-month primary patency†,1:
- 81.6% overall
- 97.1% NIVL
- 76.5% aDVT
- 70.4% PT
Product details
Simplicity for you1,2
Hear it from the expert.
Easy deployment to let you focus on your patient.1,2
The Abre™ stent minimizes jumping and foreshortening, landing precisely where you need it.2
Rotating thumbwheel offers predictable placement and auditory feedback.2
- Isolation sheath
- Hemostatic valve
- Introducer sheath
- Retractable sheath
- Inner shaft
Durability for them.1,2
Hear it from the expert.
Demonstrated endurance to give your patients freedom of movement.1,2
The nitinol Abre™ stent maintains lumen integrity and flow in diverse patients and anatomies.1 It ensures radial strength and crush resistance, without compromising flexibility.2
Unique technology:
- Open-cell design with three offset connection points
- Struts customized to each size
Consistent behavior across a broad range of diameters and lengths.2
Bench evidence shows long-term durability.2 Clinical evidence shows real-world dependability, even in challenging cases.1
- 0% fracture rate in clinical trial with 44% of stents extending below inguinal ligament into the CFV‡,1
- 0% migration rate in clinical trial1
Ordering information
Stent diameter (mm) | Stent length (mm) | |||||
---|---|---|---|---|---|---|
40 | 60 | 80 | 100 | 120 | 150 | |
10 | AB9U10040090 | AB9U10060090 | AB9U10080090 | AB9U10100090 | AB9U10120090 | AB9U10150090 |
12 | — | AB9U12060090 | AB9U12080090 | AB9U12100090 | AB9U12120090 | AB9U12150090 |
14 | — | AB9U14060090 | AB9U14080090 | AB9U14100090 | AB9U14120090 | AB9U14150090 |
16 | — | AB9U16060090 | AB9U16080090 | AB9U16100090 | AB9U16120090 | AB9U16150090 |
18 | — | AB9U18060090 | AB9U18080090 | AB9U18100090 | AB9U18120090 | AB9U18150090 |
20 | — | AB9U20060090 | AB9U20080090 | AB9U20100090 | AB9U20120090 | AB9U20150090 |
Related links
† Primary patency was defined as meeting all of the following: freedom from occlusion or restenosis ≥ 50% of the stented segment of the target lesion and freedom from clinically driven target lesion revascularization.
‡ Site and core lab data were used.
- Abre™ venous stent instructions for use.
- Test data on file at Medtronic. Report 10558227DOC_Rev A. Bench test results may not be indicative of clinical performance.